

## 6 Literaturverzeichnis

1. Martin, X.D., Normal intraocular pressure in man. *Ophthalmologica*, 1992. **205**(2): p. 57-63.
2. Medeiros, F.A., et al., Intraocular pressure fluctuations in medical versus surgically treated glaucomatous patients. *J Ocul Pharmacol Ther*, 2002. **18**(6): p. 489-98.
3. Leskea, M.C., et al., Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. *Curr Opin Ophthalmol*, 2004. **15**(2): p. 102-6.
4. Flammer, J., et al., Vascular dysregulation: a principal risk factor for glaucomatous damage? *J Glaucoma*, 1999. **8**(3): p. 212-9.
5. Kaufmann, P.L., Aqueous humor outflow. *Current Topics in Eye Research*, 1984. **4**: p. 97-138.
6. Rohen, J.W. and E. Lütjen-Drecoll, Morphology of aqueous outflow pathways in normal and glaucomatous eyes, in *The Glaucomas*, R. Ritch, M.B. Shields, and T. Krupin, Editors. 1989, Mosby Company, St. Louis, MO. p. 41-74.
7. Brandt, J.D. and M.E. O'Donnell, How does the trabecular meshwork regulate outflow? Clues from the vascular endothelium. *J Glaucoma*, 1999. **8**(5): p. 328-39.
8. Gong, H., R.C. Tripathi, and B.J. Tripathi, Morphology of the aqueous outflow pathway. *Microsc Res Tech*, 1996. **33**(4): p. 336-67.
9. Tripathi, R.C. and B.J. Tripathi, Contractile protein alteration in trabecular endothelium in primary open-angle glaucoma. *Exp Eye Res*, 1980. **31**(6): p. 721-4.
10. Tamura, M., et al., Immunofluorescence studies of the cytoskeletal and contractile elements in cultured human trabecular cells. *Jpn J Ophthalmol*, 1989. **33**(1): p. 95-102.
11. de Kater, A.W., S.J. Spurr-Michaud, and I.K. Gipson, Localization of smooth muscle myosin-containing cells in the aqueous outflow pathway. *Invest Ophthalmol Vis Sci*, 1990. **31**(2): p. 347-53.

12. Coroneo, M.T., et al., Electrical and morphological evidence for heterogeneous populations of cultured bovine trabecular meshwork cells. *Exp Eye Res*, 1991. **52**(4): p. 375-88.
13. Flugel, C., E. Tamm, and E. Lutjen-Drecoll, Different cell populations in bovine trabecular meshwork: an ultrastructural and immunocytochemical study. *Exp Eye Res*, 1991. **52**(6): p. 681-90.
14. Grierson, I., Glaucoma and nitric oxide. *Lancet*, 1996. **347**(9018): p. 1781-2.
15. Lutjen-Drecoll, E., Functional morphology of the trabecular meshwork in primate eyes. *Prog Retin Eye Res*, 1999. **18**(1): p. 91-119.
16. Barany, E.H., The mode of action of pilocarpine on outflow resistance in the eye of a primate (*Cercopithecus ethiops*). *Invest Ophthalmol*, 1962. **1**: p. 712-27.
17. Epstein, D.L., L.L. Rowlette, and B.C. Roberts, Acto-myosin drug effects and aqueous outflow function. *Invest Ophthalmol Vis Sci*, 1999. **40**(1): p. 74-81.
18. Rohen, J.W. and D. Voth, On the Comparative Anatomy and Histochemistry of the Primate Eye. *Verh Anat Ges*, 1964. **58**: p. 418.
19. Lepple-Wienhues, A., F. Stahl, and M. Wiederholt, Differential smooth muscle-like contractile properties of trabecular meshwork and ciliary muscle. *Exp Eye Res*, 1991. **53**(1): p. 33-8.
20. Wiederholt, M., A. Sturm, and A. Lepple-Wienhues, Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. *Investigative Ophthalmology and Visual Science*, 1994. **35**(5): p. 2515-2520.
21. Wiederholt, M., et al., Regulation of outflow rate and resistance in the perfused anterior segment of the bovine eye. *Exp Eye Res*, 1995. **61**: p. 223-234.
22. Wiederholt, M., et al., Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. *German Journal of Ophthalmology*, 1996. **5**: p. 146-153.

23. Shade, D.L., A.F. Clark, and I.H. Pang, Effects of muscarinic agents on cultured human trabecular meshwork cells. *Experimental Eye Research*, 1996. **62**(3): p. 201-10.
24. Wiederholt, M., N. Dörschner, and J. Groth, Effect of diuretics, channel modulators and signal interceptors on contractility of the trabecular meshwork. *Ophthalmologica*, 1997. **211**: p. 153-160.
25. Wiederholt, M., Direct involvement of trabecular meshwork in the regulation of aqueous humor outflow. *Curr Opin Ophthalmol*, 1998. **9**;II: p. 46-49.
26. Wiederholt, M. and F. Stumpff, The trabecular meshwork and aqueous humor reabsorption, in In "The eye`s aqueous humor. From Secretion to Glaucoma", *Current Topics in Membranes*, M.M. Civan, Editor. 1998, Academic Press: San Diego. p. 163-202.
27. Wiederholt, M., J. Groth, and O. Strauß, Role of protein kinases on regulation of trabecular meshwork and ciliary muscle contractility. *Investigative Ophthalmology and Visual Science*, 1998. **39**: p. 1012-1020.
28. Yanagisawa, M., et al., A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*, 1988. **332**(6163): p. 411-5.
29. Inoue, A., et al., The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc Natl Acad Sci U S A*, 1989. **86**(8): p. 2863-7.
30. Sakurai, T., M. Yanagisawa, and T. Masaki, Molecular characterization of endothelin receptors. *Trends Pharmacol Sci*, 1992. **13**(3): p. 103-8.
31. Davenport, A.P., International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. *Pharmacol Rev*, 2002. **54**(2): p. 219-26.
32. Marsault, R., E. Feolde, and C. Frelin, Receptor externalization determines sustained contractile responses to endothelin-1 in the rat aorta. *Am J Physiol*, 1993. **264**(3 Pt 1): p. C687-93.

33. Yanagisawa, M. and T. Masaki, Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. *Biochem Pharmacol*, 1989. **38**(12): p. 1877-83.
34. Shyamala, V., et al., Two distinct human endothelin B receptors generated by alternative splicing from a single gene. *Cell Mol Biol Res*, 1994. **40**(4): p. 285-96.
35. Douglas, S.A., et al., Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein. *Br J Pharmacol*, 1995. **114**(8): p. 1529-40.
36. Clozel, M. and G.A. Gray, Are there different ETB receptors mediating constriction and relaxation? *J Cardiovasc Pharmacol*, 1995. **26 Suppl 3**: p. S262-4.
37. Luscher, T.F. and R.R. Wenzel, Endothelin and endothelin antagonists: pharmacology and clinical implications. *Agents Actions Suppl*, 1995. **45**: p. 237-53.
38. Lepple-Wienhues, A., et al., Endothelin-like immunoreactivity in the aqueous humour and in conditioned medium from cultured ciliary epithelial cells. *Curr Eye Res*, 1992. **11**(11): p. 1041-6.
39. Prasanna, G., et al., Eyeing endothelins: a cellular perspective. *Mol Cell Biochem*, 2003. **253**(1-2): p. 71-88.
40. Howard, P.G., C. Plumpton, and A.P. Davenport, Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. *J Hypertens*, 1992. **10**(11): p. 1379-86.
41. Battistini, B., P. D'Orleans-Juste, and P. Sirois, Endothelins: circulating plasma levels and presence in other biologic fluids. *Lab Invest*, 1993. **68**(6): p. 600-28.
42. Noske, W., J. Hensen, and M. Wiederholt, Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. *Graefe's Archive for Clinical and Experimental Ophthalmology*, 1997. **235**(9): p. 551-2.
43. Haefliger, I.O., J. Flammer, and T.F. Luscher, Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. *Invest Ophthalmol Vis Sci*, 1992. **33**(7): p. 2340-3.

44. Haefliger, I.O., et al., The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? *Surv Ophthalmol*, 1994. **39**(2): p. 123-32.
45. Pang, I.H. and T. Yorio, Ocular actions of endothelins. *Proceedings of the Society for Experimental Biology and Medicine*, 1997. **215**(1): p. 21-34.
46. Gass, A., et al., Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients. *Graefes Arch Clin Exp Ophthalmol*, 1997. **235**(10): p. 634-8.
47. Haefliger, I.O., et al., Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. *Surv Ophthalmol*, 1999. **43 Suppl 1**: p. S51-8.
48. Stokely, M.E., S.T. Brady, and T. Yorio, Effects of endothelin-1 on components of anterograde axonal transport in optic nerve. *Invest Ophthalmol Vis Sci*, 2002. **43**(10): p. 3223-30.
49. Lepple-Wienhues, A., et al., Endothelin-evoked contractions in bovine ciliary muscle and trabecular meshwork: interaction with calcium, nifedipine and nickel. *Curr Eye Res*, 1991. **10**(10): p. 983-9.
50. Narumiya, S., Y. Sugimoto, and F. Ushikubi, Prostanoid receptors: structures, properties, and functions. *Physiol Rev*, 1999. **79**(4): p. 1193-226.
51. Kulkarni, P.S., The role of endogenous eicosanoids in rabbit-intraocular inflammation. *J Ocul Pharmacol*, 1991. **7**(3): p. 227-41.
52. Toris, C.B. and J.E. Pederson, Aqueous humor dynamics in experimental iridocyclitis. *Invest Ophthalmol Vis Sci*, 1987. **28**(3): p. 477-81.
53. Cantor, L.B., An update on bimatoprost in glaucoma therapy. *Expert Opin Pharmacother*, 2002. **3**(12): p. 1753-62.
54. Al-Jazzaf, A.M., L. DeSantis, and P.A. Netland, Travoprost: a potent ocular hypotensive agent. *Drugs Today (Barc)*, 2003. **39**(1): p. 61-74.
55. Hylton, C. and A.L. Robin, Update on prostaglandin analogs. *Curr Opin Ophthalmol*, 2003. **14**(2): p. 65-9.

56. Perry, C.M., et al., Latanoprost : an update of its use in glaucoma and ocular hypertension. *Drugs Aging*, 2003. **20**(8): p. 597-630.
57. Nguyen, Q.H., The role of prostaglandin analogues in the treatment of glaucoma in the 21st century. *Int Ophthalmol Clin*, 2004. **44**(2): p. 15-27.
58. Resul, B., et al., Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. *J Med Chem*, 1993. **36**(2): p. 243-8.
59. Stjernschantz, J., et al., Preclinical pharmacology of latanoprost, a phenyl-substituted PGF<sub>2</sub> alpha analogue. *Adv Prostaglandin Thromboxane Leukot Res*, 1995. **23**: p. 513-8.
60. Sharif, N.A., et al., Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. *J Ocul Pharmacol Ther*, 2003. **19**(6): p. 501-15.
61. Nilsson, S.F., et al., Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F<sub>2</sub> alpha-1-isopropylester in the cynomolgus monkey. *Exp Eye Res*, 1989. **48**(5): p. 707-16.
62. Tamm, E., M. Rittig, and E. Lutjen-Drecoll, [Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F<sub>2</sub> alpha]. *Fortschr Ophthalmol*, 1990. **87**(6): p. 623-9.
63. Lindsey, J.D., et al., Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. *Invest Ophthalmol Vis Sci*, 1997. **38**(11): p. 2214-23.
64. Schachtschabel, U., J.D. Lindsey, and R.N. Weinreb, The mechanism of action of prostaglandins on uveoscleral outflow. *Curr Opin Ophthalmol*, 2000. **11**(2): p. 112-5.
65. Weinreb, R.N., et al., Effects of prostaglandins on the aqueous humor outflow pathways. *Surv Ophthalmol*, 2002. **47 Suppl 1**: p. S53-64.
66. Weinreb, R.N., et al., Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. *Invest Ophthalmol Vis Sci*, 1997. **38**(13): p. 2772-80.

67. Gatton, D.D., et al., Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. *Arch Ophthalmol*, 2001. **119**(8): p. 1165-70.
68. Ocklind, A., Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. *Exp Eye Res*, 1998. **67**(2): p. 179-91.
69. Rittig, M., et al., Type-VI collagen in the human iris and ciliary body. *Cell Tissue Res*, 1990. **259**(2): p. 305-12.
70. Lindsey, J.D., et al., Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. *Surv Ophthalmol*, 1997. **41 Suppl 2**: p. S53-9.
71. Toris, C.B., et al., Aqueous humor dynamics in the aging human eye. *Am J Ophthalmol*, 1999. **127**(4): p. 407-12.
72. Flügel, C., et al., Age related loss of  $\alpha$ -smooth muscle actin in normal and glaucomatous human trabecular meshwork of different age groups. *Journal of Glaucoma*, 1992. **1**: p. 165-173.
73. Grynkiewicz, G., M. Poenie, and R.Y. Tsien, A new generation of  $Ca^{2+}$  indicators with greatly improved fluorescence properties. *J Biol Chem*, 1985. **260**(6): p. 3440-50.
74. Cobbold, P.H. and T.J. Rink, Fluorescence and bioluminescence measurement of cytoplasmic free calcium. *Biochem J*, 1987. **248**(2): p. 313-28.
75. Yousufzai, S.Y., A.L. Chen, and A.A. Abdel-Latif, Species differences in the effects of prostaglandins on inositol trisphosphate accumulation, phosphatidic acid formation, myosin light chain phosphorylation and contraction in iris sphincter of the mammalian eye: interaction with the cyclic AMP system. *J Pharmacol Exp Ther*, 1988. **247**(3): p. 1064-72.
76. Woodward, D.F., et al., Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation. *Invest Ophthalmol Vis Sci*, 1989. **30**(8): p. 1838-42.

77. Yousufzai, S.Y. and A.A. Abdel-Latif, Tyrosine kinase inhibitors suppress prostaglandin F<sub>2</sub>α-induced phosphoinositide hydrolysis, Ca<sup>2+</sup> elevation and contraction in iris sphincter smooth muscle. *Eur J Pharmacol*, 1998. **360**(2-3): p. 185-93.
78. Coleman, R.A., W.L. Smith, and S. Narumiya, International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol Rev*, 1994. **46**(2): p. 205-29.
79. Pierce, K.L., et al., Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. *J Biol Chem*, 1997. **272**(2): p. 883-7.
80. Abramovitz, M., et al., Cloning and expression of a cDNA for the human prostanoid FP receptor. *J Biol Chem*, 1994. **269**(4): p. 2632-6.
81. Sakamoto, K., et al., Molecular cloning and expression of a cDNA of the bovine prostaglandin F<sub>2</sub> α receptor. *J Biol Chem*, 1994. **269**(5): p. 3881-6.
82. Sugimoto, Y., et al., Cloning and expression of a cDNA for mouse prostaglandin F receptor. *J Biol Chem*, 1994. **269**(2): p. 1356-60.
83. Kiriya, M., et al., Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. *Br J Pharmacol*, 1997. **122**(2): p. 217-24.
84. Ocklind, A., et al., Localization of the prostaglandin F<sub>2</sub> α receptor messenger RNA and protein in the cynomolgus monkey eye. *Invest Ophthalmol Vis Sci*, 1996. **37**(5): p. 716-26.
85. Anthony, T.L., et al., Prostaglandin F<sub>2</sub> α receptors in the human trabecular meshwork. *Invest Ophthalmol Vis Sci*, 1998. **39**(2): p. 315-21.
86. Fujino, H., et al., Differential regulation of prostaglandin F<sub>2</sub>α receptor isoforms by protein kinase C. *Mol Pharmacol*, 2000. **57**(2): p. 353-8.
87. Honjo, M., et al., A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. *Exp Eye Res*, 2002. **75**(2): p. 135-42.



88. Cho, Y.J., et al., Adenosine triphosphate-induced heterologous desensitization of endothelin-1- and glutamate-evoked calcium increases in cultured rat cortical astrocytes. *Neurosci Lett*, 2000. **286**(1): p. 33-6.
89. Rachdaoui, N. and L.E. Nagy, Endothelin-1-stimulated glucose uptake is desensitized by tumor necrosis factor-alpha in 3T3-L1 adipocytes. *Am J Physiol Endocrinol Metab*, 2003. **285**(3): p. E545-51.
90. Berridge, M.J., P. Lipp, and M.D. Bootman, The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol*, 2000. **1**(1): p. 11-21.
91. Malarkey, K., et al., The regulation of tyrosine kinase signalling pathways by growth factor and G-protein-coupled receptors. *Biochem J*, 1995. **309 ( Pt 2)**: p. 361-75.
92. Duncan, G. and D.J. Collison, Calcium signalling in ocular tissues: functional activity of G-protein and tyrosine-kinase coupled receptors. *Exp Eye Res*, 2002. **75**(4): p. 377-89.
93. Sharif, N.A., C.R. Kelly, and J.Y. Crider, Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. *Invest Ophthalmol Vis Sci*, 2003. **44**(2): p. 715-21.
94. Choritz, L., et al., Pharmacological and functional characterization of endothelin receptors in bovine trabecular meshwork and ciliary muscle. *Ophthalmic Res*, 2005. **37**(4): p. 179-87.
95. Thieme, H., et al., Effects of unoprostone and endothelin 1 on L-type channel currents in human trabecular meshwork cells. *Ophthalmic Res*, 2005. **37**(6): p. 293-300.
96. Thieme, H., et al., The effects of protein kinase C on trabecular meshwork and ciliary muscle contractility. *Invest Ophthalmol Vis Sci*, 1999. **40**(13): p. 3254-61.
97. Lepple Wienhues, A., et al., Effects of endothelin and calcium channel blockers on membrane voltage and intracellular calcium in cultured bovine trabecular meshwork cells. *German Journal of Ophthalmology*, 1992. **1**: p. 159-163.

98. Somlyo, A.P. and A.V. Somlyo, Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. *J Physiol*, 2000. **522 Pt 2**: p. 177-85.
99. Thieme, H., et al., Mediation of Calcium-Independent Contraction in Trabecular Meshwork through Protein Kinase C and Rho-A. *Invest Ophthalmol Vis Sci*, 2000. **41(13)**: p. 4240-4246.
100. Honjo, M., et al., Effects of rho-associated protein kinase inhibitor, Y-27632, on intraocular pressure and aqueous humor dynamics in the rabbit eye. *Investigative Ophthalmology and Visual Sciences*, 2000. **41(4)**: p. #2715-B961.
101. Rao, P.V., et al., Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. *Invest Ophthalmol Vis Sci*, 2001. **42(5)**: p. 1029-37.
102. Allen, B.G. and M.P. Walsh, The biochemical basis of the regulation of smooth muscle contraction. *Trends in Pharmacological Sciences*, 1994. **15**: p. 362-368.
103. Tian, B., et al., H-7 increases trabecular facility and facility after ciliary muscle disinsertion in monkeys. *Investigative Ophthalmology and Visual Science*, 1999. **40(1)**: p. 239-242.
104. Sakurai, T., et al., cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. *Biochem Biophys Res Commun*, 1991. **175(1)**: p. 44-7.
105. Yorio, T., R. Krishnamoorthy, and G. Prasanna, Endothelin: is it a contributor to glaucoma pathophysiology? *J Glaucoma*, 2002. **11(3)**: p. 259-70.
106. Boulanger, C. and T.F. Luscher, Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. *J Clin Invest*, 1990. **85(2)**: p. 587-90.
107. Emori, T., et al., Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. *Hypertension*, 1991. **18(2)**: p. 165-70.
108. Yoshimoto, S., et al., Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. *Stroke*, 1991. **22(3)**: p. 378-83.
109. Wagner, O.F., et al., Polar secretion of endothelin-1 by cultured endothelial cells. *J Biol Chem*, 1992. **267(23)**: p. 16066-8.

110. Karne, S., C.K. Jayawickreme, and M.R. Lerner, Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from *Xenopus laevis* dermal melanophores. *J Biol Chem*, 1993. **268**(25): p. 19126-33.
111. Kumar, C., et al., Cloning and characterization of a novel endothelin receptor from *Xenopus* heart. *J Biol Chem*, 1994. **269**(18): p. 13414-20.
112. Hosoda, K., et al., Cloning and expression of human endothelin-1 receptor cDNA. *FEBS Lett*, 1991. **287**(1-2): p. 23-6.
113. Sakamoto, A., et al., Cloning and functional expression of human cDNA for the ETB endothelin receptor. *Biochem Biophys Res Commun*, 1991. **178**(2): p. 656-63.
114. Hirata, Y., et al., Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. *Biochem Biophys Res Commun*, 1988. **154**(3): p. 868-75.
115. Van Renterghem, C., et al., Molecular mechanism of action of the vasoconstrictor peptide endothelin. *Biochem Biophys Res Commun*, 1988. **157**(3): p. 977-85.
116. Highsmith, R.F., D.C. Pang, and R.M. Rapoport, Endothelial cell-derived vasoconstrictors: mechanisms of action in vascular smooth muscle. *J Cardiovasc Pharmacol*, 1989. **13 Suppl 5**: p. S36-44; discussion S45.
117. Marsden, P.A., et al., Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilization. *Biochem Biophys Res Commun*, 1989. **158**(1): p. 86-93.
118. Sokolovsky, M., Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. *Pharmacol Ther*, 1995. **68**(3): p. 435-71.
119. Hirata, Y., et al., Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. *J Clin Invest*, 1993. **91**(4): p. 1367-73.
120. el-Mowafy, A.M. and A.A. Abdel-Latif, Characterization of iris sphincter smooth muscle endothelin receptor subtypes which are coupled to cyclic AMP formation and polyphosphoinositide hydrolysis. *J Pharmacol Exp Ther*, 1994. **268**(3): p. 1343-51.

121. Masaki, T., Possible role of endothelin in endothelial regulation of vascular tone. *Annu Rev Pharmacol Toxicol*, 1995. **35**: p. 235-55.
122. Pinet, F., What is the role of endothelin system? *Med Sci (Paris)*, 2004. **20**(3): p. 339-45.
123. Prasanna, G., et al., Inhibition of Na(+)/K(+)-atpase by endothelin-1 in human nonpigmented ciliary epithelial cells. *J Pharmacol Exp Ther*, 2001. **296**(3): p. 966-71.
124. Krishnamoorthy, R.R., et al., Regulation of Na,K-ATPase expression by endothelin-1 in transformed human ciliary non-pigmented epithelial (HNPE) cells. *J Ocul Pharmacol Ther*, 2003. **19**(5): p. 465-81.
125. MacCumber, M.W., H.D. Jampel, and S.H. Snyder, Ocular effects of the endothelins. Abundant peptides in the eye. *Arch Ophthalmol*, 1991. **109**(5): p. 705-9.
126. Kiel, J.W., Endothelin modulation of choroidal blood flow in the rabbit. *Exp Eye Res*, 2000. **71**(6): p. 543-50.
127. Prasanna, G., et al., Human optic nerve head astrocytes as a target for endothelin-1. *Invest Ophthalmol Vis Sci*, 2002. **43**(8): p. 2704-13.
128. Oku, H., et al., Experimental optic cup enlargement caused by endothelin-1-induced chronic optic nerve head ischemia. *Surv Ophthalmol*, 1999. **44 Suppl 1**: p. S74-84.
129. Neufeld, A.H., Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. *Surv Ophthalmol*, 1999. **43 Suppl 1**: p. S129-35.
130. MacCumber, M.W. and S.A. D'Anna, Endothelin receptor-binding subtypes in the human retina and choroid. *Arch Ophthalmol*, 1994. **112**(9): p. 1231-5.
131. Thieme, H., et al., Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. *Invest Ophthalmol Vis Sci*, 2006. **47**(3): p. 938-45.
132. Ansari, H.R., et al., Effects of prostaglandin F2alpha and latanoprost on phosphoinositide turnover, myosin light chain phosphorylation and contraction in cat iris sphincter. *J Ocul Pharmacol Ther*, 2003. **19**(3): p. 217-31.

133. Ansari, H.R., I. Kaddour-Djebbar, and A.A. Abdel-Latif, Effects of prostaglandin F<sub>2</sub>alpha, latanoprost and carbachol on phosphoinositide turnover, MAP kinases, myosin light chain phosphorylation and contraction and functional existence and expression of FP receptors in bovine iris sphincter. *Exp Eye Res*, 2004. **78**(2): p. 285-96.
134. Hayami, K. and K. Unoki, Photoreceptor protection against constant light-induced damage by isopropyl unoprostone, a prostaglandin F<sub>2</sub>alpha) metabolite-related compound. *Ophthalmic Res*, 2001. **33**(4): p. 203-9.
135. Kimura, I., et al., Effects of topical isopropyl unoprostone on optic nerve head and retinal circulation. *Investigative Ophthalmology and Visual Science*, 2000. **41**(4): p. 2933.
136. Stjernschantz, J., et al., Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. *Prog Retin Eye Res*, 2000. **19**(4): p. 459-96.